J. Thistlethwaite to Muromonab-CD3
This is a "connection" page, showing publications J. Thistlethwaite has written about Muromonab-CD3.
Connection Strength
1.455
-
Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 1999 Sep 15; 68(5):608-16.
Score: 0.168
-
Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience. Transplant Proc. 1998 Jun; 30(4):1369-70.
Score: 0.153
-
Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy. Transplant Proc. 1997 Feb-Mar; 29(1-2):1549.
Score: 0.140
-
Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation. Transplant Proc. 1996 Aug; 28(4):2136-7.
Score: 0.135
-
OKT3 escalating dose regimens provide effective therapy for renal allograft rejection. Clin Transplant. 1996 Aug; 10(4):389-95.
Score: 0.135
-
Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. Transplant Proc. 1996 Apr; 28(2):1014.
Score: 0.132
-
General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc. 1993 Apr; 25(2 Suppl 1):16-20.
Score: 0.107
-
OKT3 induction in pediatric renal transplantation. Pediatr Nephrol. 1993 Feb; 7(1):45-9.
Score: 0.106
-
Liver transplantation in the first three months of life. Transplantation. 1998 Sep 15; 66(5):606-9.
Score: 0.039
-
Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation. 1996 Aug 15; 62(3):370-5.
Score: 0.034
-
Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation. 1996 May 15; 61(9):1365-9.
Score: 0.033
-
OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival. Kidney Int. 1996 Mar; 49(3):768-72.
Score: 0.033
-
OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies. Transplant Proc. 1995 Feb; 27(1):852-3.
Score: 0.030
-
A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 1994 Jun 15; 57(11):1537-43.
Score: 0.029
-
Immunosuppressive effects of anti-CD3 MAb and soluble co-stimulatory molecules. Transplant Proc. 1993 Feb; 25(1 Pt 1):546-7.
Score: 0.027
-
A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation. 1993 Jan; 55(1):44-50.
Score: 0.026
-
Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J Immunol. 1992 Jun 01; 148(11):3461-8.
Score: 0.025
-
Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression. J Immunol. 1992 May 01; 148(9):2756-63.
Score: 0.025
-
Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients. Am J Kidney Dis. 1989 Nov; 14(5 Suppl 2):28-34.
Score: 0.021
-
Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach. Transplant Proc. 1998 Jun; 30(4):1234-5.
Score: 0.010
-
Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. J Pediatr. 1997 Jul; 131(1 Pt 1):98-104.
Score: 0.009
-
Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal. Transplant Proc. 1997 Feb-Mar; 29(1-2):307.
Score: 0.009
-
Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. Transplant Proc. 1996 Apr; 28(2):998-9.
Score: 0.008
-
Inhibition of T-cell activation by an anti-human class I MHC reactive monoclonal antibody occurs at a point distal to TCR-CD3 mediated signal transduction. Transplant Proc. 1995 Feb; 27(1):395-7.
Score: 0.008
-
OKT3 therapy for hepatic allograft rejection. Differential response in adults and children. Transplantation. 1991 Jun; 51(6):1207-12.
Score: 0.006
-
OKT3 therapy for hepatic allograft rejection: comparison of results in adults and children. Transplant Proc. 1990 Aug; 22(4):1765-6.
Score: 0.006